CHMA Chiasma Inc.

5.3
-0.02  -0%
Previous Close 5.32
Open 5.31
Price To Book 2.3
Market Cap 222,686,936
Shares 42,016,403
Volume 446,346
Short Ratio
Av. Daily Volume 200,198
Stock charts supplied by TradingView

NewsSee all news

  1. Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  2. Chiasma to Present at the 13th Acromegaly Consensus Conference

    WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  3. Chiasma Reports Third Quarter 2019 Results

    CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA® NDA on track for submission by year-end 2019 MPOWEREDTM Phase 3 trial, designed to

  4. Chiasma Supports Acromegaly Awareness Day

    WALTHAM, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  5. Chiasma to Present at the Cantor 2019 Global Healthcare Conference

    WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing due 4Q 2019.
Mycapssa - OPTIMAL
Acromegaly
CRL April 15 2016
Mycapssa
Acromegaly
Phase 3 data due 2H 2020.
Mycapssa - MPOWERED
Maintenance treatment of adult acromegaly

Latest News

  1. Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  2. Chiasma to Present at the 13th Acromegaly Consensus Conference

    WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  3. Chiasma Reports Third Quarter 2019 Results

    CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA® NDA on track for submission by year-end 2019 MPOWEREDTM Phase 3 trial, designed to

  4. Chiasma Supports Acromegaly Awareness Day

    WALTHAM, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  5. Chiasma to Present at the Cantor 2019 Global Healthcare Conference

    WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  6. Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a

  7. Chiasma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  8. Aleta Biotherapeutics Announces Appointments to Board of Directors

    Mark Leuchtenberger joins Board as Executive Chairman Eva-Lotta Allan appointed as Non-Executive Director Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular